<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma." class="clickable-image" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844309/bin/koni-08-12-1665976-g001.jpg"/> </div> <div class="text-side"> <h1>HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.</h1> <p>HVEM expression scoring.(a) Our developed HVEM expression score (see Materials and Methods) revealed the broad and heterogeneous pattern of HVEM expression at the surface of melanoma cells. (b) Representative section of four melanoma metastases (a–d; magnification: X200) and of a normal skin control (e; magnification: X100) stained for HVEM. Four representative TMA spots were taken from each melanoma metastases sample (melanoma cells identified with black triangles) and each was ranked as 0: negative, absence of signal (panel a), 1: weak and inferior to the level of HVEM signal on lymphocytes (*) (panel b); 2: intermediate signal, equal to the level of HVEM signal on lymphocytes (panel c), and 3: intense signal, superior to the level of HVEM signal on lymphocytes (panel d). The sum of the intensities of the four TMA spots provided a score of 0–12. Note that in the normal skin section shown in panel e, HVEM is only expressed by sebaceous glands. (c) Distribution of high and low HVEM expression scores among melanoma metastatic sites assessed by immunohistochemistry.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31741766/" target="_blank">31741766</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>